导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 1.11% | 2131/4773 |
| 近一周 | -1.88% | 3059/5465 |
| 近一月 | -6.01% | 4000/5421 |
| 近一季 | -13.37% | 4140/5231 |
| 近半年 | -4.34% | 2791/4920 |
| 近一年 | 5.10% | 1762/4394 |
| 近两年 | 75.54% | 915/2954 |
| 近三年 | 41.86% | 722/2253 |
| 成立以来 | 20.70% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-0.37% 1774/4961 |
21.30% 1180/5312 |
- - |
- - |
| 2025 | 32.76% 1162/4813 |
1.31% 1651/3635 |
0.70% 2587/4076 |
29.75% 1206/4524 |
0.29% 2075/4813 |
| 2024 | 12.32% 1252/3463 |
-1.21% 1196/2808 |
-4.55% 1524/3014 |
19.60% 827/3129 |
-0.40% 1409/3463 |
| 2023 | -12.17% 1454/2656 |
6.22% 709/2280 |
-5.10% 1370/2385 |
-7.67% 1604/2515 |
-5.63% 1431/2655 |
| 2022 | -24.33% 1208/2207 |
-18.08% 1297/1919 |
6.89% 579/2016 |
-15.43% 1286/2113 |
2.18% 1017/2208 |
| 2021 | 8.53% 473/1822 |
-3.30% 795/1255 |
12.01% 352/1330 |
-3.75% 659/1466 |
4.10% 369/1822 |
| 2020 | 42.54% 263/1250 |
-4.44% 367/1028 |
20.95% 254/1067 |
9.07% 677/1164 |
13.07% 398/1184 |
| 2019 | 45.67% 148/1092 |
36.59% 84/754 |
-6.46% 509/804 |
3.37% 255/850 |
10.31% 148/918 |
| 2018 | -33.39% 551/834 |
- - |
- - |
- - |
-13.67% 547/691 |
| 2017 | 9.67% 305/714 |
- - |
- - |
- - |
- - |
| 2016 | -18.69% 424/605 |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 港股医疗ETF | 1.4546 | 31.90% |
| 华富中证港股通创新药指数型发起式A | 1.1637 | 30.96% |
| 天弘恒生沪深港创新药精选50ETF发起联接A | 1.3128 | 30.52% |
| 中欧中证港股通创新药指数发起A | 1.6103 | 30.52% |
| 嘉实中证港股通创新药指数发起式C | 0.8566 | 30.50% |
| 中欧中证港股通创新药指数发起C | 1.4583 | 30.44% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8927 | 30.26% |
| 景顺长城中证港股通创新药ETF联接C | 1.4696 | 29.97% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8736 | 29.94% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8719 | 29.88% |
| 大成深证成份ETF VS. 长安沪深300非周期A(740101) |